Exploring the biology of persistent type 2 airway niches in asthma

探索哮喘持续性 2 型气道生态位的生物学

基本信息

  • 批准号:
    10681265
  • 负责人:
  • 金额:
    $ 243.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-15 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

Summary / Abstract This is a renewal application for a PPG that focuses on mechanisms of persistence of type 2 inflammation in asthma. The central theme of our PPG is that the focal nature of type 2 inflammation that occurs in asthma reflects the development of persistent “type 2 airway niches” that are characterized by epithelial cell and immune cell reprogramming and mucus plug formation. Normal homeostatic responses to aeroallergens and other inhaled insults include communications between epithelial cells and innate cells to recruit adaptive cells that limit type 2 immune responses and restore airway function. When these repair mechanisms fail the normal airway immune program is replaced by adaptive responses that favor persistence of airway type 2 inflammation and formation of mucus plugs. This persistent and “ultra high” type 2 inflammation occurs in focal regions of the asthma lung, as evidenced by our recent finding of focal and persistent eosinophilic mucus plugs in lung images from patients with asthma. Our PPG will explore the biology of these focal type 2 airway niches in three overarching aims. AIM 1 will determine how innate and adaptive immune cells in the persistent airway type 2 niche are reprogrammed to sustain inflammation. AIM 2 will determine how airway epithelial cells are reprogrammed in type 2 niches to sustain inflammation. AIM 3 will determine how epithelial cells and eosinophils sustain mucus gel pathology in type 2 airway niches. Our PPG comprises three projects led by multidisciplinary teams of clinical scientists, immunologists and cell biologists. The projects are supported by three cores - administration, human subjects, and biospecimens and bioinformatics. Our PPG proposes innovative concepts for the pathogenesis of type 2-high asthma and it will deploy powerful and cutting edge technologies in the experimental approaches that address our program aims. We are united in our ambition to aim for discoveries that have the potential to lead to curative treatments for type 2-high asthma.
摘要/摘要 这是对PPG的续订应用,该PPG专注于2型炎症在 哮喘。我们PPG的中心主题是哮喘发生的2型炎症的局灶性 反映了以上皮细胞和免疫为特征的持续性“2型呼吸道小生境”的发展。 细胞重新编程和粘液堵塞的形成。对空气过敏原和其他过敏原的正常稳态反应 吸入性侮辱包括上皮细胞和固有细胞之间的通讯,以招募限制 第二型免疫反应和恢复呼吸道功能。当这些修复机制失效时,正常的呼吸道 免疫程序被适应性反应所取代,这种适应性反应有利于呼吸道2型炎症的持续和 粘液堵塞的形成。这种持续性的“超高”2型炎症发生在 哮喘肺,我们最近在肺部影像中发现的局限性和持续性嗜酸性粘液塞证明了这一点 来自哮喘患者。我们的PPG将在三年内探索这些焦点2型呼吸道壁龛的生物学 首要目标。目标1将确定持续性呼吸道2型中的先天免疫细胞和获得性免疫细胞 小生境被重新编程以维持炎症。目标2将确定呼吸道上皮细胞如何 在2型壁龛中重新编程以维持炎症。目标3将确定上皮细胞和嗜酸性粒细胞如何 在2型气道壁龛中维持粘液凝胶病理。我们的PPG由三个项目组成,由多学科领导 由临床科学家、免疫学家和细胞生物学家组成的团队。这些项目由三个核心支持- 管理、人类受试者、生物标本和生物信息学。我们的PPG提出创新的概念 对于2型高哮喘的发病机制,它将部署强大的尖端技术 针对我们的计划目标的实验方法。我们在追求发现的雄心上是一致的。 有可能导致治疗II型高度哮喘的药物。

项目成果

期刊论文数量(69)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Influenza virus infection increases ACE2 expression and shedding in human small airway epithelial cells.
  • DOI:
    10.1183/13993003.03988-2020
  • 发表时间:
    2021-07
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Schweitzer KS;Crue T;Nall JM;Foster D;Sajuthi S;Correll KA;Nakamura M;Everman JL;Downey GP;Seibold MA;Bridges JP;Serban KA;Chu HW;Petrache I
  • 通讯作者:
    Petrache I
MicroRNA regulation of allergic inflammation and asthma.
  • DOI:
    10.1016/j.coi.2015.07.006
  • 发表时间:
    2015-10
  • 期刊:
  • 影响因子:
    7
  • 作者:
    Pua HH;Ansel KM
  • 通讯作者:
    Ansel KM
Small RNA Transfection in Primary Human Th17 Cells by Next Generation Electroporation.
下一代电穿孔中原代人Th17细胞中的小RNA转染。
In Situ Maturation and Tissue Adaptation of Type 2 Innate Lymphoid Cell Progenitors.
  • DOI:
    10.1016/j.immuni.2020.09.002
  • 发表时间:
    2020-10-13
  • 期刊:
  • 影响因子:
    32.4
  • 作者:
    Zeis P;Lian M;Fan X;Herman JS;Hernandez DC;Gentek R;Elias S;Symowski C;Knöpper K;Peltokangas N;Friedrich C;Doucet-Ladeveze R;Kabat AM;Locksley RM;Voehringer D;Bajenoff M;Rudensky AY;Romagnani C;Grün D;Gasteiger G
  • 通讯作者:
    Gasteiger G
A role for IL-33-activated ILC2s in eosinophilic vasculitis.
IL-33 激活的 ILC2 在嗜酸性血管炎中的作用。
  • DOI:
    10.1172/jci.insight.143366
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    8
  • 作者:
    Kotas,MayaE;Dion,Jérémie;VanDyken,Steven;Ricardo-Gonzalez,RobertoR;Danel,ClaireJ;Taillé,Camille;Mouthon,Luc;Locksley,RichardM;Terrier,Benjamin
  • 通讯作者:
    Terrier,Benjamin
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John V Fahy其他文献

Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts
开发哮喘保健负担评分作为 SARP III 和 U-BIOPRED 中严重程度的衡量指标和缓解预测因子:来自两个主要纵向哮喘队列的结果
  • DOI:
    10.1016/s2213-2600(24)00250-9
  • 发表时间:
    2025-01-01
  • 期刊:
  • 影响因子:
    32.800
  • 作者:
    Joe G Zein;Nazanin Zounemat-Kermani;Ian M Adcock;Bo Hu;Amy Attaway;Mario Castro;Sven-Erik Dahlén;Loren C Denlinger;Serpil C Erzurum;John V Fahy;Benjamin Gaston;Annette T Hastie;Elliot Israel;Nizar N Jarjour;Bruce D Levy;David T Mauger;Wendy Moore;Michael C Peters;Kaharu Sumino;Elizabeth Townsend;Eugene R Bleecker
  • 通讯作者:
    Eugene R Bleecker

John V Fahy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John V Fahy', 18)}}的其他基金

Evaluating the Impact of Metabolic Dysfunction on Asthma Pathology and Physiology
评估代谢功能障碍对哮喘病理学和生理学的影响
  • 批准号:
    10688260
  • 财政年份:
    2022
  • 资助金额:
    $ 243.9万
  • 项目类别:
Evaluating the Impact of Metabolic Dysfunction on Asthma Pathology and Physiology
评估代谢功能障碍对哮喘病理学和生理学的影响
  • 批准号:
    10503780
  • 财政年份:
    2022
  • 资助金额:
    $ 243.9万
  • 项目类别:
Sequential, Multiple Assignment, Randomized Trial in Severe Asthma Protocol (SMART-SA)
严重哮喘方案中的序贯、多重分配、随机试验 (SMART-SA)
  • 批准号:
    10454345
  • 财政年份:
    2017
  • 资助金额:
    $ 243.9万
  • 项目类别:
Sequential, Multiple Assignment, Randomized Trial in Severe Asthma Protocol (SMART-SA)
严重哮喘方案中的序贯、多重分配、随机试验 (SMART-SA)
  • 批准号:
    10221035
  • 财政年份:
    2017
  • 资助金额:
    $ 243.9万
  • 项目类别:
Sequential, Multiple Assignment, Randomized Trial in Severe Asthma Protocol (SMART-SA)
严重哮喘方案中的序贯、多重分配、随机试验 (SMART-SA)
  • 批准号:
    9751962
  • 财政年份:
    2017
  • 资助金额:
    $ 243.9万
  • 项目类别:
Carbohydrate-based Therapy for Lung Disease
以碳水化合物为基础的肺部疾病治疗
  • 批准号:
    9766888
  • 财政年份:
    2016
  • 资助金额:
    $ 243.9万
  • 项目类别:
A thiol-saccharide therapy to treat COVID-19
治疗 COVID-19 的硫醇糖疗法
  • 批准号:
    10226074
  • 财政年份:
    2016
  • 资助金额:
    $ 243.9万
  • 项目类别:
Carbohydrate-based Therapy for Lung Disease
以碳水化合物为基础的肺部疾病治疗
  • 批准号:
    10225939
  • 财政年份:
    2016
  • 资助金额:
    $ 243.9万
  • 项目类别:
Carbohydrate-based Therapy for Lung Disease
以碳水化合物为基础的肺部疾病治疗
  • 批准号:
    9147792
  • 财政年份:
    2016
  • 资助金额:
    $ 243.9万
  • 项目类别:
Epithelial cell reprogramming and mucus gel pathology in self-sustaining type 2 airway niches in asthma
哮喘自我维持型 2 型气道微环境中的上皮细胞重编程和粘液凝胶病理学
  • 批准号:
    10226878
  • 财政年份:
    2012
  • 资助金额:
    $ 243.9万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 243.9万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 243.9万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 243.9万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 243.9万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 243.9万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 243.9万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 243.9万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 243.9万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 243.9万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 243.9万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了